The World Hepatitis C Support Project provides access to affordable Hepatitis C treatment at the lowest possible price.
The World Hepatitis C Support Project aims to provide Hepatitis C treatment at the lowest possible price to people in low income situations in all the nations of the Earth. Hepatitis C treatment is now available to any person in a low income situation for the cost of only US$350 for 12 weeks treatment including delivery to anywhere on Earth.
The World Hepatitis C Support Project is an initiative of Hep C activist Greg Jefferys and the Australian based company Affordable Medical Access International.
The World Hepatitis C Support Project aims to supply licensed generic Hepatitis C medication to any person in a low-income situation requesting treatment. This Hepatitis C medication will be supplied at the lowest possible price, which is currently US$350 for 12 weeks treatment; including delivery.
The price of US$350 represents the World Hepatitis C Support Project’s purchase price of the medicine plus a small margin to cover the WHP’s operating overheads.
There is no requirement for a person to prove their low-income status; in the World Hepatitis C Support Project we believe that the vast majority of humanity is honest and so a person only needs ask for our support and we will give it.
So to qualify for accessing Hepatitis C treatment through the World Hepatitis C Support Project you simply have to state that you are in a low income situation by telling us your monthly income and we will supply the Hep C medication to you.
The most cost-effective treatment for Hepatitis C currently available is the combination of Sofosbuvir 400 mg + Daclatasvir 60 mg. This combination is equal to, or better than, Mavyret as a treatment for all the genotypes of Hepatitis C.
Sofosbuvir + Daclatasvir is also equal to, or better than, Harvoni for treating Hep C genotype 1.
Sofosbuvir + Daclatasvir is also equal to Epclusa for treating genotype 3 and all other genotypes except when a person has cirrhosis.
The World Hepatitis C Support Project will supply a 12 week treatment of Sofosbuvir 400 mg + Daclatasvir 60 mg for a total price of US$350. This price includes all delivery costs to any country on Earth.
Delivery is either by EMS express airmail or by Registered Post, depending on what is the best option for the country that the delivery is going to.
The Sofosbuvir that the Hepatitis C Support Project supplies is licensed by Gilead (the patent holder) and the Daclatasvir is licensed by Bristol Myer Squib (the patent holder).
The actual medication is manufactured either by the USA based pharmaceutical company Mylan or the Indian based pharmaceutical company Hetero. Both companies are approved and certified by the World Health Organisation and by the US FDA.
Unlike almost all other Hepatitis C advocacy groups the World Hepatitis C Support Project does not accept funding from Big Pharma, this Project is totally self funded.
Whilst being self funded limits our resources and access to capital that would allow us to buy Hepatitis C medication in bulk so we would to be able to supply Hepatitis C treatment for less than US$350, being self funded gives us independence. Because we are a completely self-funded organisation with no corporate “sponsors” we can not be bought off, bribed or influenced by Big Pharma like other Hep C organisations.
For example the World Hepatitis Alliance receives almost 100% of its funding from Big Pharma and, as a result does not advocate for the best outcomes for people with Hepatitis C, rather the World Hepatitis Allience advocates for the best outcome for Big Pharma.
Because we are self funded we need to cover our operating expenses within the price of the medication. However everyone who works for the World Hepatitis C Support Project gets below the Australian average weekly wage.
We are working to help people access affordable Hepatitis C treatment, not to enrich ourselves.
Yes, we do have a very small profit margin, but it is the absolute smallest margin that we can have and still be able to keep operating.
We strongly believe that access to affordable medical treatment is a basic human right and that lack of money should not be a barrier to accessing treatment. For this reason, we put people before profits.